Continuous High-Frequency Oscillation Therapy in Invasively Ventilated Pediatric Subjects in the Critical Care Setting.

BACKGROUND: Continuous high-frequency oscillation (CHFO) creates a pressure gradient in the small airways that accelerates expiratory flow. The intended use of CHFO therapy is to facilitate secretion removal and treat atelectasis. Our objective was to assess the feasibility, safety, and efficacy of...

Descripción completa

Detalles Bibliográficos
Publicado en:Respiratory Care Vol. 61; no. 11; pp. 1451 - 1456
Autores principales: Morgan, Stephen, Hornik, Christoph P., Patel, Niyati, Williford, Walter L., Turner, David A., Cheifetz, Ira M.
Formato: research tables/charts Journal Article
Publicado: Mary Ann Liebert, Inc. Nov2016
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=119227664&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 119227664
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00201324
        4GG
      jtl: Respiratory Care
      issn: 00201324
      maglogo: N
    pubinfo:
      dt: Nov2016
      vid: 61
      iid: 11
      pid: 1365
      pub: Mary Ann Liebert, Inc.
      place: New Rochelle, New York
    artinfo:
      ui:
        119227664
        119227664
        119227664
        10.4187/respcare.04368
        119227664
      ppf: 1451
      ppct: 5
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Continuous High-Frequency Oscillation Therapy in Invasively Ventilated Pediatric Subjects in the Critical Care Setting.
      aug:
        au:
          Morgan, Stephen
          Hornik, Christoph P.
          Patel, Niyati
          Williford, Walter L.
          Turner, David A.
          Cheifetz, Ira M.
        affil: Respiratory Care Services, Duke University Hospital, Duke University Medical Center, Durham, North Carolina
      sug:
        subj:
          Ventilator Patients In Infancy and Childhood
          Critical Care In Infancy and Childhood
          Ventilation, High Frequency In Infancy and Childhood
          Pulmonary Atelectasis Therapy
          Human
          Infant
          Child, Preschool
          Child
          Record Review
          Medical Records
          Descriptive Research
          Descriptive Statistics
          Blood Gas Analysis
          Vital Signs Evaluation
          Adolescence
          Administration, Inhalation
          Wilcoxon Signed Rank Test
          Funding Source
          Infant: 1-23 months
          Child, Preschool: 2-5 years
          Child: 6-12 years
          Adolescent: 13-18 years
      ab: BACKGROUND: Continuous high-frequency oscillation (CHFO) creates a pressure gradient in the small airways that accelerates expiratory flow. The intended use of CHFO therapy is to facilitate secretion removal and treat atelectasis. Our objective was to assess the feasibility, safety, and efficacy of CHFO in the mechanically ventilated pediatric population. METHODS: After institutional review board approval, we retrospectively reviewed medical records of mechanically ventilated children treated with CHFO (the MetaNeb system) at our institution from July 1,2007 through August 31,2012. Patients supported with extracorporeal membrane oxygenation were excluded. We evaluated changes in ventilator settings in subjects with ventilator data documented within 6h pre- and post-treatment. We evaluated arterial blood gas (ABG) results for individual treatments, comparing ABG results within 8 h pre-therapy to ABG results within 3 h post-treatment. Oxygen index and ... were calculated. Demographic data, blood pressure, heart rate, and development of new air leak while being treated with CHFO were recorded. Pre- and post-CHFO measurements were compared using Wilcoxon signed-rank testing. RESULTS: Our cohort included 59 invasively ventilated subjects. Median age was 2 y (range 1 month to 19 y), and median weight was 14 kg (2-81 kg). We evaluated data on 528 total treatments (range per subject 1-39 treatments). Peak inspiratory pressure significantly decreased with CHFO, whereas other parameters, including ... and breathing frequency, remained stable. There was no significant change in systolic blood pressure, diastolic blood pressure, or heart rate following treatment with CHFO. One subject (2%) developed a clinically insignificant pneumothorax during CHFO. CONCLUSIONS: CHFO is feasible and seems safe in our cohort of mechanically ventilated pediatric subjects. The rate of pneumothorax was consistent with that seen in similar pediatric ICU populations. These preliminary results suggest that CHFO may be beneficial by improving lung compliance in pediatric subjects with secretion-induced atelectasis. Prospective clinical studies are needed to further evaluate the clinical efficacy and safety of CHFO in children receiving invasive mechanical ventilation
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N